Search the database for deliberate release of GM medicinal products
Displaying 1 - 1 of 1
|EU record number
|Company / Sponsor
|A phase IIa partial blind, placebo-controlled clinical trial to evaluate the safety and immunogenicity of the Ad5-EBOV in healthy adults aged between 18 and 60 years in Belgium.
|Bejing Institute of Biotechnology, CanSino Biologics Inc,
|Recombinant Adenoviral vector serotype 5 expressing the envelop glycoprotein from Ebola virus (Zaïre-Makona)